UK markets closed

Laboratorios Farmaceuticos Rovi, S.A. (0ILL.L)

LSE - LSE Delayed price. Currency in EUR
Add to watchlist
84.30+1.75 (+2.12%)
At close: 05:01PM BST
Currency in EUR

Valuation measures4

Market cap (intra-day) N/A
Enterprise value N/A
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)N/A
Price/book (mrq)N/A
Enterprise value/revenue N/A
Enterprise value/EBITDA N/A

Trading information

Stock price history

Beta (5Y monthly) 0.49
52-week change 392.29%
S&P500 52-week change 323.10%
52-week high 379.76
52-week low 30.00
50-day moving average 367.54
200-day moving average 353.85

Share statistics

Avg vol (3-month) 311.27k
Avg vol (10-day) 310.37k
Shares outstanding 549.31M
Implied shares outstanding 6N/A
Float 819.28M
% held by insiders 160.25%
% held by institutions 118.46%
Shares short 4N/A
Short ratio 4N/A
Short % of float 4N/A
Short % of shares outstanding 4N/A
Shares short (prior month ) 4N/A

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 31.10
Trailing annual dividend yield 31.34%
5-year average dividend yield 4N/A
Payout ratio 4N/A
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Dec 2023

Profitability

Profit margin 20.53%
Operating margin (ttm)28.23%

Management effectiveness

Return on assets (ttm)16.34%
Return on equity (ttm)31.98%

Income statement

Revenue (ttm)829.51M
Revenue per share (ttm)15.34
Quarterly revenue growth (yoy)-3.10%
Gross profit (ttm)N/A
EBITDA 243.8M
Net income avi to common (ttm)170.34M
Diluted EPS (ttm)3.32
Quarterly earnings growth (yoy)-34.10%

Balance sheet

Total cash (mrq)25.32M
Total cash per share (mrq)0.49
Total debt (mrq)65.43M
Total debt/equity (mrq)12.04%
Current ratio (mrq)2.55
Book value per share (mrq)10.41

Cash flow statement

Operating cash flow (ttm)113.25M
Levered free cash flow (ttm)25.34M